Journal Article

Suggested guidelines for the diagnosis and management of urea cycle disorders

Häberle, Johannes, Martinelli, Diego, Lindner, Martin, Chakrapani, Anupam, Dionisi-Vici, Carlo, Karall, Daniela, Santer, René, Servais, Aude, Huemer, Martina, Rubio, Vicente, Crespo, Pablo Sanjurjo, Valayannopoulos, Vassili, Burlina, Alberto, Dixon, Marjorie, Boddaert, Nathalie

2012

Overview

Urea cycle disorders (UCDs) are inborn errors of ammonia detoxification/arginine synthesis due to defects affecting the catalysts of the Krebs-Henseleit cycle (five core enzymes, one activating enzyme and one mitochondrial ornithine/citrulline antiporter) with an estimated incidence of 1:8.000. Patients present with hyperammonemia either shortly after birth (~50%) or, later at any age, leading to death or to severe neurological handicap in many survivors. Despite the existence of effective therapy with alternative pathway therapy and liver transplantation, outcomes remain poor. This may be related to underrecognition and delayed diagnosis due to the nonspecific clinical presentation and insufficient awareness of health care professionals because of disease rarity. These guidelines aim at providing a trans-European consensus to: guide practitioners, set standards of care and help awareness campaigns. To achieve these goals, the guidelines were developed using a Delphi methodology, by having professionals on UCDs across seven European countries to gather all the existing evidence, score it according to the SIGN evidence level system and draw a series of statements supported by an associated level of evidence. The guidelines were revised by external specialist consultants, unrelated authorities in the field of UCDs and practicing pediatricians in training. Although the evidence degree did hardly ever exceed level C (evidence from non-analytical studies like case reports and series), it was sufficient to guide practice on both acute and chronic presentations, address diagnosis, management, monitoring, outcomes, and psychosocial and ethical issues. Also, it identified knowledge voids that must be filled by future research. We believe these guidelines will help to: harmonise practice, set common standards and spread good practices with a positive impact on the outcomes of UCD patients.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Ammonia / Arginase 1 / Argininosuccinate lyase / Argininosuccinate synthetase / Carbamoylphosphate synthetase 1 / Care and treatment / Child / Child, Preschool / Diagnosis / Diagnosis, Differential / Dietary Proteins - administration & dosage / Endorsements / Gene mutations / Genetic aspects / Health aspects / Human Genetics / Humans / Hyperammonemia / Hyperammonemia - diagnosis / Hyperammonemia - therapy / Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome / Infant / Infant, Newborn / Intensive care / Ligases / Liver / Medical research / Medicine / Medicine & Public Health / Meetings / Metabolic disorders / Metabolism, Inborn errors of / Mortality / N-acetylglutamate synthase / Neonatal Screening / Ornithine carbamoyl transferase / Ornithine transcarbamylase / Pediatrics / Pharmacology/Toxicology / Practice guidelines (Medicine) / Practice Guidelines as Topic / Prenatal Diagnosis / Rare diseases / Review / Risk factors / Transplantation / UCD / Urea / Urea cycle disorders / Urea Cycle Disorders, Inborn - diagnosis / Urea Cycle Disorders, Inborn - genetics / Urea Cycle Disorders, Inborn - therapy